Here's what I think IMUN could get to within a few months (after commercialization begins)...
From Rainmaker's sticky note (and the January investor conference call)...
One tablet of LDN costs .84 for the patient.
Of that, IMUN will earn .24 profit.
.24 x 150,000 patients x 365 days (each patient takes 1 pill per day) = 13.14m profit per year
Keep in mind 150,000 patients is the number they expect to reach by only the 3rd month. They will continue to acquire more patients, and will also continue to expand into many new countries.
Noreen projected (during the January conference call) that we'll eventually reach around 300m shares outstanding. We're at 287m as of April 28th.
My brokerage account says the Industry Average Price / Earnings ratio for Biotech is 56.98. Anybody know what it is specifically for penny stocks?
My guess is that IMUN's P/E ratio will be lower than the industry average, but how low could the ratio really be? I have no idea, but let's just assume it will trade at a P/E ratio of 15. That's giving a very conservative estimate, and I believe Noreen's estimates in January were also conservative.
15 x 13.14m = $197.1m (market cap)
197.1m / 300m = $0.657 per share.
If future growth gets priced in, or if P/E ratio gets higher than a modest 15, this thing could get over $1 before the end of the year.
And the risk to reach there is whether or not NAFDAC says IMUN's manufacturing plant has passed inspection? Pretty insane odds IMO.
News 
Market Data 
Discover 
